Literature DB >> 24692376

Misdiagnosis of common variable immune deficiency.

Anne-Marie Shanks1, Ratna Alluri, Richard Herriot, Owen Dempsey.   

Abstract

We present details of a man who was originally diagnosed with sarcoidosis, based on a combination of nodal granulomatous inflammation and radiology confirming bilateral hilar lymphadenopathy with pulmonary infiltrates. The patient subsequently developed splenomegaly and idiopathic thrombocytopenic purpura (ITP) and, latterly, a severe cavitating pneumonia. Serum immunoglobulins were checked, confirming panhypogammaglobulinaemia, and his diagnosis was revised to common variable immune deficiency (CVID). CVID is a heterogeneous condition, which can mimic sarcoidosis with granulomatous organ involvement and is commonly complicated by autoimmune disorders, including ITP. Prompt recognition is important to allow early introduction of immunoglobulin replacement therapy to decrease infection frequency, reduce development of secondary disease complications and retard progression of tissue damage. Given the potential for misdiagnosis and delay in recognition of CVID, serum immunoglobulin measurement should be a first-line investigation in patients with suspected sarcoidosis, even if the presentation is 'typical'. Current international sarcoidosis guidelines should be revised accordingly.

Entities:  

Mesh:

Year:  2014        PMID: 24692376      PMCID: PMC3987550          DOI: 10.1136/bcr-2013-202806

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

Review 1.  Current perspectives on common variable immunodeficiency (CVID).

Authors:  G P Spickett
Journal:  Clin Exp Allergy       Date:  2001-04       Impact factor: 5.018

Review 2.  How I treat common variable immune deficiency.

Authors:  Charlotte Cunningham-Rundles
Journal:  Blood       Date:  2010-03-23       Impact factor: 22.113

3.  Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.

Authors:  B Bradley; H M Branley; J J Egan; M S Greaves; D M Hansell; N K Harrison; N Hirani; R Hubbard; F Lake; A B Millar; W A H Wallace; A U Wells; M K Whyte; M L Wilsher
Journal:  Thorax       Date:  2008-09       Impact factor: 9.139

Review 4.  Sarcoidosis.

Authors:  Owen J Dempsey; Edward W Paterson; Keith M Kerr; Alan R Denison
Journal:  BMJ       Date:  2009-08-28

Review 5.  Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

Review 6.  Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID).

Authors:  Joon H Park; Arnold I Levinson
Journal:  Clin Immunol       Date:  2009-11-08       Impact factor: 3.969

7.  Granulomatous disease in common variable immunodeficiency.

Authors:  Omür Ardeniz; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2009-08-28       Impact factor: 3.969

  7 in total
  3 in total

Review 1.  Granulomatous-Lymphocytic Interstitial Lung Disease in 22q11.2 Deletion Syndrome: a Case Report and Literature Review.

Authors:  Amika K Sood; William Funkhouser; Brian Handly; Brent Weston; Eveline Y Wu
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-22       Impact factor: 4.806

Review 2.  Sarcoidosis: Pitfalls and Challenging Mimickers.

Authors:  Naureen Narula; Michael Iannuzzi
Journal:  Front Med (Lausanne)       Date:  2021-01-11

3.  The critical role of histology in distinguishing sarcoidosis from common variable immunodeficiency disorder (CVID) in a patient with hypogammaglobulinemia.

Authors:  Rohan Ameratunga; Yeri Ahn; Dominic Tse; See-Tarn Woon; Jennifer Pereira; Sinead McCarthy; Hilary Blacklock
Journal:  Allergy Asthma Clin Immunol       Date:  2019-12-02       Impact factor: 3.406

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.